Nuveen
KPTI icon

Nuveen’s Karyopharm Therapeutics KPTI Stock Holding History

Nuveen’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$80K Buy
65,578
+27,710
+73% +$113K ﹤0.01% 4074
2026
Q2 		$370K Buy
+37,868
New +$328K ﹤0.01% 3417
2024
Q2 		– Sell
-32,824
Closed -$743K – 3379
2024
Q1 		$743K Buy
32,824
+2,537
+8% +$44.5K ﹤0.01% 2824
2023
Q4 		$393K Buy
30,287
+127
+0.4% +$1.71K ﹤0.01% 3080
2023
Q3 		$606K Sell
30,160
-742
-2% -$16.7K ﹤0.01% 2779
2023
Q2 		$830K Sell
30,902
-87,667
-74% -$3.78M ﹤0.01% 2734
2023
Q1 		$6.92M Buy
118,569
+12,322
+12% +$608K ﹤0.01% 1703
2022
Q4 		$5.42M Sell
106,247
-25,156
-19% -$1.74M ﹤0.01% 1863
2022
Q3 		$10.8M Buy
131,403
+5,044
+4% +$377K ﹤0.01% 1430
2022
Q2 		$8.55M Buy
126,359
+5,089
+4% +$467K ﹤0.01% 1616
2022
Q1 		$11.9M Buy
121,270
+42,316
+54% +$5.27M ﹤0.01% 1538
2021
Q4 		$6.72M Buy
78,954
+4,353
+6% +$434K ﹤0.01% 1933
2021
Q3 		$6.79M Sell
74,601
-1,127
-1% -$117K ﹤0.01% 2050
2021
Q2 		$11.7M Buy
75,728
+13,757
+22% +$2M ﹤0.01% 1764
2021
Q1 		$9.8M Sell
61,971
-6,535
-10% -$1.38M ﹤0.01% 1816
2020
Q4 		$15.9M Sell
68,506
-1,643
-2% -$381K 0.01% 1393
2020
Q3 		$15.4M Buy
70,149
+41,966
+149% +$10.3M 0.01% 1225
2020
Q2 		$8.01M Buy
28,183
+9,235
+49% +$2.73M ﹤0.01% 1637
2020
Q1 		$5.46M Sell
18,948
-11,875
-39% -$3.28M ﹤0.01% 1664
2019
Q4 		$8.86M Buy
30,823
+4,255
+16% +$923K ﹤0.01% 1657
2019
Q3 		$3.83M Buy
26,568
+854
+3% +$116K ﹤0.01% 2102
2019
Q2 		$2.31M Buy
+25,714
New +$2.06M ﹤0.01% 2369
2014
Q3 		– Sell
-725
Closed -$506K – 1616
2014
Q2 		$506K Buy
725
+30
+4% +$14K ﹤0.01% 1365
2014
Q1 		$322K Sell
695
-542
-44% -$275K ﹤0.01% 1418
2013
Q4 		$425K Buy
+1,237
New +$342K ﹤0.01% 1351

Other funds holding KPTI

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Nuveen's KPTI Position: Q3 2026 in Review

Nuveen increased its Karyopharm Therapeutics (KPTI) stake by 73% in Q3 2026, buying an estimated $113K and bringing the position to 65,578 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #4074.

Nuveen first reported a position in KPTI in Q4 2013 and has held it in 25 quarters since. The position peaked at $15.9M in Q4 2020. 39 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Nuveen held 65,578 shares of Karyopharm Therapeutics worth $80K as of Q3 2026.
  • Nuveen bought 27,710 Karyopharm Therapeutics shares in Q3 2026, an estimated $113K.
  • Karyopharm Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4074 holding.
  • Nuveen first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 25 quarters since.
  • Nuveen's Karyopharm Therapeutics position peaked at $15.9M in Q4 2020.
  • 39 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.